Skip to Content
Print Share

Generic Imbruvica Availability

Imbruvica is a brand name of ibrutinib, approved by the FDA in the following formulation(s):

IMBRUVICA (ibrutinib - capsule;oral)

  • Manufacturer: PHARMACYCLICS INC
    Approval date: November 13, 2013
    Strength(s): 140MG [RLD]

Has a generic version of Imbruvica been approved?

No. There is currently no therapeutically equivalent version of Imbruvica available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imbruvica. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Inhibitors of bruton's tyrosine kinase
    Patent 7,514,444
    Issued: April 7, 2009
    Inventor(s): Honigberg; Lee & Verner; Erik & Pan; Zhengying
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhibitors of bruton's tyrosine kinase
    Patent 8,008,309
    Issued: August 30, 2011
    Inventor(s): Honigberg; Lee & Verner; Erik & Pan; Zhengying
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhibitors of Bruton's tyrosine kinase
    Patent 8,476,284
    Issued: July 2, 2013
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds, including compounds having the Formula (A) where A, R1, R2, R3, and R4 are as defined in the specification, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    • December 28, 2026
      ✓ 
      Patent use: TREATMENT OF MANTLE CELL LYMPHOMA
    • December 28, 2026
  • Inhibitors of Bruton's tyrosine kinase
    Patent 8,497,277
    Issued: July 30, 2013
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Patent use: TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
    • December 28, 2026
      ✓ 
      Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    • December 28, 2026
    • December 28, 2026
      ✓ 
      Patent use: TREATMENT OF MANTLE CELL LYMPHOMA
  • Inhibitors of bruton'S tyrosine kinase
    Patent 8,697,711
    Issued: April 15, 2014
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhibitors of Bruton's tyrosine kinase
    Patent 8,703,780
    Issued: April 22, 2014
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
  • Inhibitors of Bruton's tyrosine kinase
    Patent 8,735,403
    Issued: May 27, 2014
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Use of inhibitors of bruton's tyrosine kinase (Btk)
    Patent 8,754,090
    Issued: June 17, 2014
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Patent expiration dates:
    • June 3, 2031
      ✓ 
      Patent use: TREATMENT OF MANTLE CELL LYMPHOMA
  • Inhibitors of bruton's tyrosine kinase
    Patent 8,754,091
    Issued: June 17, 2014
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug product
  • Inhibitors of Bruton's tyrosine kinase
    Patent 8,957,079
    Issued: February 17, 2015
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure: Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent 8,999,999
    Issued: April 7, 2015
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Patent expiration dates:
    • June 3, 2031
      ✓ 
      Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    • June 3, 2031
      ✓ 
      Patent use: TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent 9,125,889
    Issued: September 8, 2015
    Assignee(s): Pharmacyclics, Inc.
    Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Patent expiration dates:
    • June 3, 2031
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
  • Inhibitors of Bruton's tyrosine kinase
    Patent 9,181,257
    Issued: November 10, 2015
    Assignee(s): PHARMACYCLICS LLC
    Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • December 28, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline forms of a Bruton's tyrosine kinase inhibitor
    Patent 9,296,753
    Issued: March 29, 2016
    Assignee(s): Pharmacyclics LLC
    Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • October 30, 2033
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline forms of a Bruton's tyrosine kinase inhibitor
    Patent 9,540,382
    Issued: January 10, 2017
    Assignee(s): Pharmacyclics LLC
    Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Patent expiration dates:
    • August 18, 2033
      ✓ 
      Patent use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    • August 18, 2033
    • August 18, 2033
      ✓ 
      Patent use: TREATMENT OF MANTLE CELL LYMPHOMA
    • August 18, 2033
    • August 18, 2033
      ✓ 
      Patent use: TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 12, 2017 - TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
    • July 28, 2017 - TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
    • January 29, 2018 - FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
    • November 13, 2018 - NEW CHEMICAL ENTITY
    • March 4, 2019 - PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    • May 6, 2019 - REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
    • May 6, 2019 - REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
    • May 6, 2019 - DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
    • January 18, 2020 -
    • November 13, 2020 - ORPHAN DRUG EXCLUSIVITY
    • February 12, 2021 - ORPHAN DRUG EXCLUSIVITY
    • July 28, 2021 - ORPHAN DRUG EXCLUSIVITY
    • January 29, 2022 - ORPHAN DRUG EXCLUSIVITY
    • March 4, 2023 - ORPHAN DRUG EXCLUSIVITY
    • May 6, 2023 - ORPHAN DRUG EXCLUSIVITY
    • January 18, 2024 - ORPHAN DRUG EXCLUSIVITY
Add to My Med List

More about Imbruvica (ibrutinib)

Consumer resources

Professional resources

Related treatment guides

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide